DrugPatentWatch Database Preview

Drugs in Development Information for Gossypol

Email this page to a colleague

« Back to Dashboard

What is the drug development status for Gossypol?

Gossypol is an investigational drug.

There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1^st 2013.

The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.

There is one US patent protecting this investigational drug and seven international patents.

Summary for Gossypol

US Patents	1,126
International Patents	7,980
US Patent Applications	3,501
WIPO Patent Applications	1,565
Japanese Patent Applications	1,248
Clinical Trial Progress	Phase 2 (2013-09-01)
Vendors	94

Recent Clinical Trials for Gossypol

Title	Sponsor	Phase
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma	National Cancer Institute (NCI)	Phase 1/Phase 2
R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma	Mayo Clinic	Phase 1/Phase 2
Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia	National Cancer Institute (NCI)	Phase 1/Phase 2

See all Gossypol clinical trials

Clinical Trial Summary for Gossypol

Top disease conditions for Gossypol

Top clinical trial sponsors for Gossypol

See all Gossypol clinical trials

US Patents for Gossypol

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Gossypol		Heterocyclic compounds useful in the treatment of disease	Epigen Biosciences, Inc. (San Diego, CA)
Gossypol		Pyrazol-3-ones that activate pro-apoptotic BAX	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Gossypol		Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders	Dana-Farber Cancer Institute, Inc. (Boston, MA)
Gossypol		Methods for sensitizing a quiescent cancer stem cell to a BCR-ABL inhibitor	The Regents of the University of California (Oakland, CA)
Gossypol		Methods and compositions for treating infection	UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS)
Gossypol		Precise delivery of therapeutic agents to cell mitochondria for anti-cancer therapy	University of Georgia Research Foundation Inc. (Athens, GA)

International Patents for Gossypol

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Gossypol	Australia	AU2014232383	2033-03-15
Gossypol	Australia	AU2019202731	2033-03-15
Gossypol	Brazil	BR112015023267	2033-03-15
Gossypol	Canada	CA2906931	2033-03-15
Gossypol	Canada	CA3046894	2033-03-15
Gossypol	China	CN105142635	2033-03-15